Oil prices have been sliding after expectations of lower Iran war escalation, which has taken some heat out of traditional energy stocks and pushed investors to hunt for growth in other parts of the Australian market. That shift puts fast growing businesses with significant insider ownership on many radar screens. This article walks through three such Australian stocks and explains why their growth profiles and insider backing may appeal at this time.
The three stocks highlighted here offer a compelling starting point if you want exposure to fast growing businesses where management is strongly aligned with shareholders. However, if you want the absolute best, these 27 high growth high conviction stocks are the cream of the crop.
PDI Gold (ASX:PDI)
PDI Gold is a West African gold producer focused on the Kiniéro Gold Mine in Guinea, which anchors its fast-growth profile and insider alignment. Kiniéro is generating about US$156 million of revenue versus US$47 million from Nampala, and the group is valued at around A$4 billion.
PDI Gold fits this fast-growing, insider-backed theme because its flagship Kiniéro operation is already delivering meaningful production and cash generation. Insiders also remain closely tied to the value investors are watching play out.
"Although Kiniero is ramping strongly with low reported all in sustaining costs and high throughput, the reliance on oxide ore for the next few years means a later shift to harder material could lift unit costs and pressure margins once the current "oxide holiday" ends."
What happens when one less-visible cost pressure shifts will likely dictate how much of the anticipated earnings growth actually lands in shareholders' hands.
That hinge point on future costs is exactly where the story gets interesting, so read the full narrative for PDI Gold to see how the ramp could still accelerate.
Telix Pharmaceuticals (ASX:TLX)
Telix Pharmaceuticals plugs directly into the Fast Growing Stocks With High Insider Ownership theme through its late-stage radiopharmaceutical therapies and diagnostics. TLX591 and BiPASS anchor a broader portfolio of cancer-focused imaging agents and treatments now moving from lab bench to commercial shelves.
Telix Pharmaceuticals develops and commercialises radiopharmaceutical diagnostics and therapies, with most revenue coming from Precision Medicine at about $704 million and Manufacturing Solutions at roughly $277 million, and the group valued around A$4.5 billion in market cap.
"Their primary revenue generating imaging agents: 'Illuccix' and 'Gozellix', are utilised in 23+ countries worldwide, including key markets such as the U.S, Europe, China and Japan, with revenue figures of $803.8m (USD) in the 2025 Financial Year."
What could really shift the Telix story now is how one unresolved pressure shapes the balance between aggressive pipeline spend and future profitability.
That trade off sits at the centre of Telix Pharmaceuticals right now, so read the full narrative for Telix Pharmaceuticals to see how pipeline spend and margins could be decoupling.
Barrenjoey Group (ASX:BJY)
Barrenjoey Group gives you pure exposure to actively managed global equities and listed infrastructure, which is exactly where this screener looks for fast growth supported by confident management. The business is now reshaping around that engine while still drawing income from other activities.
Barrenjoey Group is a Sydney based investment manager focused on global equities and listed infrastructure, with about A$206 million coming from Investment Management Services and roughly A$40 million from Partnerships & Investments, supporting a A$2.4b market value.
"The growth of partnership income to A$25.7 million in the first half of FY26, accounting for 31% of operating profit and supported by contributions from Barrenjoey and Vinva, points to a larger role for capital light fee streams that can affect future margins and profit mix."
What happens when a single growth lever in those high margin fee streams shifts will likely decide how much of the optimism actually sticks.
If that growth lever keeps shifting, read the full narrative for Barrenjoey Group to see how Barrenjoey Group's fee mix could accelerate or quietly cap returns.
Seeking Alternatives Before The Crowd?
Fresh breakout stories do not stay under the radar for long. Momentum gets spotted, prices move, and the easy entry points get caught and start dropping. Act now.
-
Spot resilient cash generators early by scanning the list of solid balance sheet and fundamentals (12 results) before the crowd prices in their stronger funding positions and cleaner financial profiles.
-
Ride structural demand in precious metals by tracking the 34 elite gold producer stocks that bundle producers with stronger balance sheets and production profiles while sentiment is still resetting.
-
Position ahead of infrastructure upgrades by reviewing the 41 power grid technology and infrastructure stocks that group potential beneficiaries of grid modernisation while these ideas remain under the radar for now.
This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
